Healthcare Analysts Bullish on SI-Bone, Delcath Systems, and Cardiol Therapeutics

Analysts are bullish on SI-Bone (SIBN), Delcath Systems (DCTH), and Cardiol Therapeutics (CRDL) with strong buy ratings and average price targets of $23.33, $22.75, and $9.50 respectively, implying upside of 50.9%, 115.2%, and 787.9% from current levels. TipRanks estimates analyst Caitlin Cronin's average return at 3.7% and success rate at 51.0%, while John Newman's average return is -5.0% and success rate is 34.9%. Edward Nash has a 5-star rating with an average return of 14.9% and a 45.4% success rate.

Analysts are expressing strong optimism on several healthcare stocks, with notable buy ratings and significant price targets. SI-Bone (SIBN), Delcath Systems (DCTH), and Cardiol Therapeutics (CRDL) are among the companies receiving high praise, with analysts predicting substantial upside potential.

SI-Bone, a leading medical device company specializing in minimally invasive surgical implants for the sacroiliac joint, has seen a significant worldwide revenue growth of 21.7% and a U.S. revenue increase of 22.8% in the second quarter of 2025. The company achieved a positive adjusted EBITDA and improved its gross margin to 79.8%, indicating financial stability and operational efficiency. Cantor Fitzgerald has reiterated an "Overweight" rating for SI-Bone, with a price target of $23.33, implying a 50.9% upside from the current level [2].

Delcath Systems, which markets a liver-directed chemotherapy system, has shown promising results with a revenue of $24 million in the second quarter of 2025, representing a 211% year-over-year growth and an operating margin of almost 11%. The company's HEPZATO KIT is the only approved therapy in the U.S. for metastatic uveal melanoma and is currently testing its system in metastatic breast cancer and metastatic colorectal cancer. Analysts have given Delcath Systems a strong buy rating with an average price target of $22.75, indicating a potential 115.2% upside [3].

Cardiol Therapeutics, a company developing innovative cardiovascular solutions, has received a strong buy rating from analysts with an average price target of $9.50, suggesting a 787.9% upside from current levels. The company's focus on innovative treatments for cardiovascular diseases has garnered attention from financial professionals [3].

Analysts' track records vary, with Caitlin Cronin showing an average return of 3.7% and a success rate of 51.0%, while John Newman's average return is -5.0% with a success rate of 34.9%. Edward Nash, on the other hand, has a 5-star rating with an average return of 14.9% and a 45.4% success rate, demonstrating his consistent performance in the market [1].

Investors should closely monitor these companies' performance and consider the potential for significant growth based on the analysts' ratings and price targets. However, it is essential to conduct thorough research and consider all available information before making any investment decisions.

References:
[1] https://www.ainvest.com/news/si-bone-15-min-chart-shows-rsi-oversold-kdj-golden-cross-2508-25/
[2] https://site.financialmodelingprep.com/market-news/si-bone-inc-nasdaq-sibn-overweight-rating-cantor-fitzgerald
[3] https://seekingalpha.com/article/4812493-delcath-systems-huge-potential-but-with-the-handbrake-on-for-now